secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGENUS INC (AGEN)
CIK:        0001098972
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001171843-22-007211
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agenus reports Q3 net loss $56.7M, cash $218.2M; botensilimab Phase 2 trials initiated
--------------------------------------------------------------------------------

- Q3 2022 net loss $56.7M ($0.19/sh) vs prior-year net income; revenue $22.8M, down from $253M largely due to prior milestone.
- Cash and investments $218.2M vs $306.9M at Dec 2021; cash used in operations $32.2M in Q3.
- Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS colorectal cancer and melanoma.
- Expanded leadership: Patricia Carlos named Chief Regulatory, Quality & Safety Officer; Todd Yancey as Senior Clinical Advisor.
- Partner programs advancing: BMS, Merck, Incyte ongoing Phase 2/1 trials for discovered assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1098972/000117184322007211/0001171843-22-007211-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1098972/000117184322007211/f8k_110722.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-007211

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer